Opioid maker is slammed by FDA for omitting risk info in materials given to docs

In the midst of a worsening crisis over opioid use and prescribing, you might think a company would take every precaution to ensure its medicine is marketed carefully to physicians.

But one small drug maker failed to do so — in a big way.

In promotional materials that were distributed to doctors, Vertical Pharmaceuticals omitted some rather important risk information about ConZip, an opioid painkiller, according to a warning letter the Food and Drug Administration issued late last month and posted on its web site earlier this month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In